Decreased myocardial accumulation of 123i-meta-iodobenzyl guanidine in parkinson’s disease

Nuclear Medicine Communications

Volumn 19, Issue 2, 1998, Pages 137-142

  Yoshita, Mitsuhiro ^a   Hayashi, M ^a   Hirai, S ^a  

^a TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG ACCUMULATION; FEMALE; HEART SCINTISCANNING; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; MALE; PARKINSON DISEASE; SYMPATHETIC NERVE;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 0031957254     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199802000-00007     Document Type: Article

References (30)

1. Wieland DM, Brown LE, Rogers WL et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
2. Merlet P, Valette H, Dubois-Rande JL et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
3. Gill JS, Hunter GJ, Gane J, Ward DE, Lamm AJ. Asymmetry of cardiac 123I-metaiodobenzyl guanidine scans in patients with ventricular tachycardia and ‘clinically normal’ heart. Br Heart. J. 1993; 69: 6-13.
4. Mantysaari M, Kuikka J, Mustonen J et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using,23I-metaiodobenzyl guanidine. Diabetes 1992; 41: 1069-1075.
5. Sisson JC, Shapiro B, Meyers I et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
6. Appenzeller O, Goss JE. Autonomic deficits in Parkinson’s syndrome. Arch Neurol 1971; 24: 50-57.
7. Ludin SM, Steiger UH, Ludin HP. Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson’s disease. J Neurol 1987; 235: 10-15.
8. McDowell FH, Lee JE. Levodopa, Parkinson’s disease and hypotension. Ann Intern Med 1970; 72: 751-752.
9. Vanderhaegen JJ, Perrier O, Stemon JE. Pathological findings in idiopathic orthostatic hypotension. Arch Neurol 1970; 22: 207-214.
10. Aminoff MJ, Wilcox CS. Assessment of autonomic function in patients with a parkinsonian syndrome. Br Med J 1971; 4: 80-84.
11. Milon D, Allain H, Bentue-Ferrer D, Martinet JP, Lemaiture MH, Decombe R. Cardiac /3-adrenoceptor sensitivity and Parkinson’s disease. Fundam Clin Pharmacol 1991; 5: 539-548.
12. Turkka JT, Juujarvi KK, Lapinlampi TO, Myllyla VV. Autonomic dysfunction in Parkinson’s disease: Serumnoradrenaline response to standing up. J Neurol 1985; 232 (suppl.): 66.
13. Hoehn MM, Yahr MD. Parkinsonism: Progression and mortality. Neurology 1976; 17: 427-442.
14. Solanki KK, Bomanji J, Moyes J et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
15. Nakajima K, Taki J, Tonami N, Hisada K. Decreased [I23]I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994; 15: 317-323.
16. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996; 46: 1470.
17. Langston JW, Forno LS. Hypothalamus in Parkinson’s disease. Ann Neurol 1978; 3: 129-133.
18. Jager WADH, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiat 1960; 23: 283-290.
19. Rajput AH, Rozdilsky B. Dysautonomia in parkinsonism: A clinicopathological study. J Neurol Neurosurg Psychiat 1976; 39: 1092-1100.
20. Ganguly PK, Beamish RE, Dhalla KS, Innes IR, Dhalla NS. Norepinephrine stage, distribution and release in diabetic cardiomyopathy. Am J Physiol 1987; 252: E734-739.
21. Dae MW, O’Connell W, Botvinick E et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 1989; 79: 634-644.
22. Jaques S, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984; 26: 539-546.
23. Gill JS, Hunter GJ, Gane G, Ward DE, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: In vivo demonstration by iodine-123-labeled metaiodobenzyl-guanidine scintigraphy. Am Heart J 1993; 126: 390-398.
24. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. ] Nucl Med 1993; 34: 1140-1146.
25. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson’s disease and control substantia nigra neurons. Ann Neurol 1994; 35: 494-498.
26. Kitayama S, Shimada S, Uhl GR. Parkinsonism-inducing neurotoxin MPP+: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 1992; 32: 109-111.
27. Giros B, El Mestikawy S, Bertrand L, Caron GC. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 1991; 295: 149-154.
28. Hakusui S, Yasuda T, Takahashi A et al. A radiological analysis of heart sympathetic functions with meta-[123I]io-dobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994; 49: 81-84.
29. Merlet P. Clinical value of MIBG imaging in cardiology. In: Torizuka K, Hisada K, Hirosawa K, eds. Proceedings of the Third Meeting of Nuclear Medicine in Circulation. Yokohama: Nuclear Medicine in Circulation, 1994: 3: 96-111.
30. Bohm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. ] Am Coll Cardiol 1995; 25: 146-153.